Welcome to visit Zhongnan Medical Journal Press Series journal website!

Home Articles Vol 32,2023 No.7 Detail

Analysis of anti-infective therapy and pharmaceutical care for a patient with uremia and primary pulmonary lymphoma complicated with sepsis

Published on Jul. 29, 2023Total Views: 676 times Total Downloads: 179 times Download Mobile

Author: Fan-Yan MENG 1 Jiang LIU 2 Hui LIU 1 Ling ZHANG 1 Jie HU 1 Zi-Wei LIANG 1

Affiliation: 1. Department of Pharmacy, People's Hospital of Anshun City, Anshun 561000, Guizhou Province, China 2. Department of Rheumatology and Immunology, People's Hospital of Anshun City, Anshun 561000, Guizhou Province, China

Keywords: Sepsis Uremia Lung lymphoma Anti infection therapy Pharmaceutical care

DOI: 10.19960/j.issn.1005-0698.202307013

Reference: Fan-Yan MENG, Jiang LIU, Hui LIU, Ling ZHANG, Jie HU, Zi-Wei LIANG.Analysis of anti-infective therapy and pharmaceutical care for a patient with uremia and primary pulmonary lymphoma complicated with sepsis[J].Yaowu Liuxingbingxue Zazhi,2023, 32(7): 830-835.DOI: 10.19960/j.issn.1005-0698.202307013.[Article in Chinese]

  • Abstract
  • Full-text
  • References
Abstract

The clinical pharmacist participated in the treatment of a patient with uremia and primary pulmonary lymphoma complicated with sepsis, and developed a detailed individualized anti-infective treatment plan, including the selection of antibacterial drugs, the optimization of drug administration plan, etc., in combination with hemodialysis, residual renal function, the severity of infection, the pharmacokinetic/pharmacodynamic of antibacterial drugs, the dynamic changes of imaging and infection indicators, and literature. Finally, the patient's infection was effectively controlled, and good therapeutic effect was achieved. At the same time, through the implementation of pharmaceutical care, no adverse drug reactions occurred, residual renal function was fully protected, the patient received safe and effective drug treatment, and the professional value of clinical phar-macists was reflected.

Full-text
Please download the PDF version to read the full text: download
References

1.Evans L, Rhodes A, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021[J]. Intensive Care Med, 2021, 47(11): 1181-1247. DOI: 10.1007/s00134-021-06506-y.

2.中华医学会重症医学分会. 中国严重脓毒症/脓毒性休克治疗指南(2014)[J]. 中华危重病急救医学, 2015, 27(6): 401-426. DOI: 10.3760/j.issn.2095-4352.2015. 06.001.

3.Rudd KE, Johnson SC, Agesa KM, et al. Global, regional, and national sepsis incidence and mortality, 1990-2017: analysis for the Global Burden of Disease Study[J]. Lancet, 2020, 395(10219): 200-211. DOI: 10.1016/S0140-6736(19)32989-7.

4.中华医学会呼吸病学分会. 中国成人社区获得性肺炎诊断和治疗指南(2016年版)[J]. 中华结核与呼吸杂志, 2016, 39(4): 253-279. DOI: 10.3760/cma.j.issn.1001-0939.2016.04.005.

5.Sieswerda E, Bax HI, Hoogerwerf JJ, et al. The 2021 Dutch Working Party on Antibiotic Policy (SWAB) guidelines for empirical antibacterial therapy of sepsis in adults[J]. BMC Infect Dis, 2022, 22(1): 687. DOI: 10.1186/s12879-022-07653-3.

6.孙铁英. 从指南看呼吸喹诺酮类药物在下呼吸道感染中的治疗地位[J]. 临床药物治疗杂志, 2019, 17(12): 29-32, 56. [Sun TY. The role of respiratory quinolones in the treatment of lower respiratory tract infection through the view of guideline[J]. Clinical Medication Journal, 2019, 17(12): 29-32, 56.] DOI: 10.3969/j.issn.1672-3384.2019.12.007.

7.Cunha BA. Meropenem in elderly and renally impaired patients[J]. Int J Antimicrob Agents, 1999, 11(2): 167-177. DOI: 10.1016/s0924-8579(99)00040-0.

8.彭婕, 程乐. 我院73例碳青霉烯类抗菌药不良反应分析[J]. 中国药师, 2015, 18(12): 2119-2122. [Peng J, Cheng L. Analysis of 73 cases of adverse drug reactions caused by carbapenem antibiotics[J]. China Pharmacist, 2015, 18(12): 2119-2122.] DOI: 10.3969/j.issn.1008-049X.2015.12.033.

9.张金萍, 滕玉双, 宋燕青, 等. 亚胺培南/西司他丁诱发移植肾失功患者癫痫发作1例[J]. 中国药师, 2021, 24(1): 120, 126. [Zhang JP, Teng YS, Song YQ, et al. Epilepsy in a patient with renal allograft dysfunction induced by imipenem/cilastatin: a case report[J]. China Pharmacist, 2021, 24(1): 120, 126.] DOI:10.3969/j.issn.1008-049X.2021.01.025.

10.闫圣涛. 降钙素原对不同细菌感染鉴别诊断和病情评估的临床研究[D]. 北京: 北京协和医学院, 2021.

11.Metlay JP, Waterer GW, Long AC, et al. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American thoracic society and infectious dis-eases society of America[J]. Am J Respir Crit Care Med, 2019, 200(7): e45-e67. DOI: 10.1164/rccm.201908-1581ST.

12.Kalil AC, Metersky ML, Klompas M, et al. Management of adults with hospital-acquired and ventila-tor-associated pneumonia: 2016 clinical practice guidelines by the infectious diseases society of America and the American thoracic society[J]. Clin Infect Dis, 2016, 63(5): e61-e111. DOI: 10.1093/cid/ciw353.

13.中华医学会呼吸病学分会感染学组. 中国成人医院获得性肺炎与呼吸机相关性肺炎诊断和治疗指南(2018年版)[J]. 中华结核和呼吸杂志, 2018, 41(4): 255-280.DOI: 10.3760/cma.j.issn.1001-0939.2018.04.006.

14.Ghane Shahrbaf F, Assadi F. Drug-induced renal disorders[J]. J Renal Inj Prev, 2015, 4(3): 57-60. DOI: 10.12861/jrip.2015.12.

15.雷兴平, 黄春香. 血液透析患者残余肾功能保护策略研究进展[J]. 中国中西医结合肾病杂志, 2022, 23(5): 465-467. [Lei XP, Huang CX. Research progress on protective strategies of residual renal function in hemodialy-sis patients[J]. Chinese Journal of Integrated Traditional and Western Nephrology, 2022, 23(5): 465-467.] DOI: 10.3969/j.issn.1009-587X.2022.05.029.

16.陈沈珏, 胡杰, 李昕, 等. 重症医学科重症感染患者美罗培南血药浓度达标情况及影响因素分析[J]. 中国药师, 2022, 25(6): 1017-1020. [Chen SY, Hu J, Li X, et al. Analysis of clinical characteristics and influencing factors of meropenem concentration in ICU patients with serious infection[J]. China Pharmacist, 2022, 25(6): 1017-1020.]DOI: 10.19962/ j.cnki.issn1008-049X.2022.06.013.

17.齐慧生, 刘宝欣, 郭红, 等. 美罗培南联合莫西沙星治疗慢性阻塞性肺疾病感染性肺炎的疗效与安全性研究[J]. 中华医院感染学杂志, 2016, 26(9): 1967-1969. [Qi HS, Liu BX, Guo H, et al. Effect and safety of meropenem combined with moxifloxacin on treatment of chronic obstructive pulmonary disease complicated with infectious pneumonia[J]. Chinese Journal of Noso-comiology, 2016, 26(9): 1967-1969.] DOI: 10.11816/cn.ni.2016-153835.

18.钱建丹, 李俊, 霍娜, 等. 《拯救脓毒症运动: 2021年脓毒症和脓毒症休克管理国际指南》感染管理更新要点解读[J]. 中华传染病杂志, 2022, 40(7): 385-391.[Qian JD, Li J, Huo N, et al. Interpretation of key points in the in-fection management update of the surviving sepsis campaign: international guidelines for the man-agement of sepsis and septic shock 2021[J]. Chinese Journal of Infectious Diseases, 2022, 40(7): 385-391.] DOI: 10.3760/cma.j.cn311365-20211216-00445.

19.司淑一. 侵袭性肺曲霉菌病诊断进展[J]. 中国临床医生杂志, 2016, 44(7): 20-23. [Si SY. Progress in diagnosis of invasive pulmonary aspergillosis[J]. Chinese Journal for Clinicians, 2016, 44(7): 20-23.] DOI: 10.3969/j.issn.2095-8552.2016.07.007.

20.苗春萌, 张传玉. CT鉴别诊断原发性与继发性肺淋巴瘤[J]. 中国介入影像与治疗学, 2023, 20(2): 102-106. [Miao CM, Zhang CY. CT differenttial diagnosis of primary and secondary pulmonary lymphoma[J]. Chin J In-terv Imaging Ther, 2023, 20(2): 102-106.] DOI: 10.13929/j.issn.1672-8475.2023.02.010.

21.王晓妮, 张娴. 1例长期血液透析伴肺部感染患者的药学监护[J]. 中国药师, 2018, 21(10): 1817-1819.[Wang XN, Zhang X. Pharmaceutical care for one case of long-term hemodialysis complicated with pulmonary in-fection[J]. China Pharmacist, 2018, 21(10): 1817-1819.]DOI: 10.3969/j.issn.1008-049X.2018.10.031.

Popular papers
Last 6 months